![](images/graphics/blank.gif)
PD-1
-
The objective of this study was to describe real-world adjuvant therapy (AT) use by disease substage and assess determinants of treatment choice among patients with stage III melanoma. This non-interventional retrospective study included survey responses and data from patient records pro‑ vided by US medical oncologists.
13p
vishanshan
27-06-2024
2
1
Download
-
We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term benefit in these patients.
13p
vileonardodavinci
23-12-2023
6
2
Download
-
Mantle cell lymphoma (MCL) has remained incurable in most patients. The expression of PD-L1 as a prognostic and predictive marker has not been fully evaluated in MCL. The current study aimed to determine PD-1/ PD-L1 expression in MCL specimens and its significance as an immune check point inhibitor.
8p
vileonardodavinci
23-12-2023
5
4
Download
-
Accumulating evidence has revealed that the gut microbiota influences the effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. As a part of the human microbiome, Helicobacter pylori (H. pylori) was reported to be associated with reduced effectiveness of anti-PD1 immunotherapy in patients with non-small-cell lung cancer (NSCLC).
8p
vialfrednobel
23-12-2023
7
3
Download
-
With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resect‑ able metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors.
11p
visharma
20-10-2023
4
2
Download
-
Clinical trials have shown that anti-PD1 therapy, either as a monotherapy or in combination, is effective and well-tolerated in patients with recurrent or unresectable hepatocellular carcinoma (HCC). In this study, we aimed to investigate the prognostic value of immune-nutritional biomarkers in measuring the effects of anti-PD1 therapy in these patients.
14p
vioracle
29-09-2023
9
3
Download
-
Immunotherapy has emerged as a robust clinical strategy for cancer treatment. PD1/PD-L1 inhibitors have been used as second-line therapy for urothelial carcinoma due to the high tumor mutational burden. Despite the efficacy of the treatment is significant, the response rate is still poor.
13p
visusanwojcicki
28-06-2022
7
2
Download
-
In recent years, the application of immunotherapy combined with chemotherapy in the first-line lung cancer has showed signifcant beneft in improving long-term survival. Immunotherapy also has risks of immunerelated pneumonitis (IRP) after long-term treatment.
8p
vimackenziebezos
29-11-2021
13
2
Download
-
Mutant peptides presented by MHC (major histocompatibility complex) Class II in cancer are important targets for cancer immunotherapy. Both animal studies and clinical trials in cancer patients showed that CD4 T cells specific to tumor-derived mutant peptides are essential for the efficacy of immune checkpoint blockade therapy by PD1 antibody.
9p
vitzuyu2711
29-09-2021
10
1
Download
-
Anti-PD1 inhibitors have been approved for the treatment of recurrent or metastatic head and neck cancer (HNC), as a result of Global Phase III trials. However, the clinical outcomes of immune checkpoint inhibitors in patients who are not eligible for clinical trials or have various medical conditions have not been fully elucidated.
9p
vimale2711
21-08-2020
7
1
Download
-
Programmed cell death 1 (PD1) inhibitors have recently shown promising anti-cancer effects in a number of solid tumor types. A predictive biomarker to this class of drugs has not been clearly identified; however, overexpression of the PD1 ligand (PD-L1) has shown particular promise in lung adenocarcinoma.
10p
vimanama2711
30-07-2020
6
1
Download
-
Sarcomas constitute a heterogeneous group of tumors with different clinical behaviors and variable responses to systemic therapies. Recent immunotherapy studies with PD1 inhibitors (PD1i) show promising results with use in certain soft-tissue sarcomas; however, the clinical and molecular features that best predict response to PD1i remain unclear.
11p
vikuala271
13-06-2020
6
2
Download
-
Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery.
8p
vikuala271
13-06-2020
11
0
Download
-
: Bạch cầu cấp dạng tiền tủy bào (APL) là một loại bệnh bạch cầu cấp tính gây tử vong cao nhất trong số bệnh ung thư máu và được gây ra do hoạt động chuyển vị của nhiễm sắc thể 15 và 17 tạo ra tổ hợp gen PML/RAR-α. Gen klotho (KL) có vai trò ngăn chặn sự lão hóa, phản ứng viêm và ung thư. CTLA4, PD1 và LAG3 là những thụ thể kiểm soát miễn dịch nằm trên bề mặt của tế bào T và có vai trò điều hòa ngược phản ứng miễn dịch. Các gen trên điều hòa hoạt động tế bào miễn dịch thông qua một số tín hiệu phân tử như STAT và NF-κB.
9p
caothientrangnguyen
01-04-2020
47
3
Download
-
Bài giảng Thiết kế dự án: Tuần 1 do ThS. Nguyễn Thùy Dung biên soạn nhằm giới thiệu nguồn gốc môn PD, nhập môn Thiết kế dự án 1 - PD1, giới thiệu hệ thống phiếu PD, hoạt động tổ chức nhóm, nguyên tắc lớp học, thử nghiệm Mini-project, họp nhóm.
22p
sangbanmai_0906
17-01-2018
114
7
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)